Varian to acquire Cancer Treatment Services International for Rs 1980 crore

These fast-growing offerings will allow Varian to expand its solutions while helping to support the continued growth trajectory of the company’s oncology systems business.

Mumbai: Taking an important step to accelerate innovation of new multidisciplinary solutions to address the growing global cancer burden, Varian Medical Systems recently announced it has entered into a definitive agreement to acquire Cancer Treatment Services International (CTSI) for $283 million(Rs 1980 crore).

Privately held, CTSI operates the American Oncology Institute in Hyderabad and10 multidisciplinary—radiation, medical and surgical oncology—cancer centres across the Indian subcontinent as well as a U.S.-based Oncology Solutions division that provides cancer care professional services to healthcare providers worldwide.

This transaction will accelerate the identification of unmet clinical and operational needs to facilitate advances in technology and services. As a result, the combined companies will be positioned to create new multidisciplinary solutions based on robust clinical information benefiting oncologists, and ultimately resulting in better care for patients. These fast-growing offerings will allow Varian to expand its solutions while helping to support the continued growth trajectory of the company’s oncology systems business.

Also Read: Bayer Zydus Pharma to continue to invest in new medicines

Commenting on the acquisition, Dow Wilson, president and chief executive officer of Varian said, “At Varian, the patient and clinician are at the centre of our thinking as we evolve into a broad-based cancer care solutions company.”

“Our acquisition of CTSI is consistent with this strategy and will allow us to better support oncology centre globally, accelerate access to technology-driven care and build a feedback loop that will drive cost-effective innovation. We look forward to pooling the ingenuity of our combined team with the power of data, technology and clinical insights to achieve new victories against cancer, especially for the millions of patients globally without access to appropriate care,” Dow added.

This transaction will increase Varian’s expertise in cancer centre operations, allowing for new partnerships globally to deliver world-class, value-based care in developed and emerging markets. In addition, the transaction expands the scope and geographic reach of CTSI’s technology-enabled clinical solutions.

“We are excited to continue our mission to address the growing global incidence of cancer and the disparity in access to treatment between the developed and emerging markets,” said Andrew Shogan, co-founder and executive director, CTSI.

“Together with Varian, we will be better equipped to provide new solutions that empower more patients globally to fight cancer,” Andrew added.

“Effectively addressing the growing global cancer burden requires not just new technology and research, but also new ways of collaborating and partnering,” said Stanley M. Marks, M.D., co-founder of CTSI and chairman of UPMC Hillman Cancer Center.

“This acquisition should now expand the development and implementation of new solutions for cancer care around the world, ” Stanley added.

Also Read: Morgan Stanley to invest Rs 145 crore in Manipal Health Enterprise